Indication

Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With

1 clinical trial

2 products

Clinical trial

A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for Additional 2 Years in Women With Hormone-receptor Positive Breast Cancer:

Status: Active (not recruiting), Estimated PCD: 2024-01-29

Product

Product